If that was Zantrene’s only use case then i would agree
However we might be pretty close to reviewed validation of FTO as a valid target in clinical setting
A strong result in AML monotherapy with a 50+% R/R could be enough to trigger a deal
Who know’s who JC has been speaking to over the last 12-18 months gearing them up for positive P2 results in AML?
We might be looking at it like its the ugly duckling knowing what FTO & Cardio could be worth, but i assure you BP would waste no time in aquiring it if it meant a quick path to revenue and the other 2 area’s as back up.
A bird in the hand to those guys is certainly better than 999 in the bush.
If that was Zantrene’s only use case then i would agree However...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |